Cargando…

Microglial Activation and Antioxidant Responses Induced by the Parkinson’s Disease Protein α-Synuclein

Parkinson’s disease (PD) is the second most common age-related neurodegenerative disorder typified by tremor, rigidity, akinesia and postural instability due in part to the loss of dopamine within the nigrostriatal system. The pathologic features of this disorder include the loss of substantia nigra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Béraud, Dawn, Hathaway, Hannah A., Trecki, Jordan, Chasovskikh, Sergey, Johnson, Delinda A., Johnson, Jeffrey A., Federoff, Howard J., Shimoji, Mika, Mhyre, Timothy R., Maguire-Zeiss, Kathleen A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2012
Materias:	Invited Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582877/ https://www.ncbi.nlm.nih.gov/pubmed/23054368 http://dx.doi.org/10.1007/s11481-012-9401-0

Ejemplares similares

α-Synuclein Alters Toll-Like Receptor Expression
por: Béraud, Dawn, et al.
Publicado: (2011)

Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson’s Disease
por: Subramaniam, Sudhakar R., et al.
Publicado: (2017)

Parkinson-related parkin reduces α-Synuclein phosphorylation in a gene transfer model
por: Khandelwal, Preeti J, et al.
Publicado: (2010)

MMP13 Expression Is Increased Following Mutant α-Synuclein Exposure and Promotes Inflammatory Responses in Microglia
por: Sánchez, Kathryn, et al.
Publicado: (2020)

4395 alpha-Synuclein Induced Reactive Gliosis
por: Carey, Sean David, et al.
Publicado: (2020)

Heterogeneity of Microglial Activation in the Innate Immune Response in the Brain
por: Colton, Carol A.
Publicado: (2009)

Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson’s disease
por: Yoo, Hajung, et al.
Publicado: (2022)

Inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2) Protect Against LRRK2-Models of Parkinson’s Disease
por: Lee, Byoung Dae, et al.
Publicado: (2010)

Patient-specific pluripotent stem cell-based Parkinson’s disease models showing endogenous alpha-synuclein aggregation
por: Oh, Yohan
Publicado: (2019)

Automatic counting of microglial cell activation and its applications
por: Gallego, Beatriz I., et al.
Publicado: (2016)

α‐synuclein suppresses microglial autophagy and promotes neurodegeneration in a mouse model of Parkinson’s disease
por: Tu, Hai‐Yue, et al.
Publicado: (2021)

Immune Responses in Parkinson's Disease: Interplay between Central and Peripheral Immune Systems
por: Su, Xiaomin, et al.
Publicado: (2014)

Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson’s Disease
por: Li, Yunna, et al.
Publicado: (2021)

Navigating the dynamic landscape of alpha-synuclein morphology: a review of the physiologically relevant tetrameric conformation
por: Lucas, Heather R., et al.
Publicado: (2019)

Clearing the corpses: regulatory mechanisms, novel tools, and therapeutic potential of harnessing microglial phagocytosis in the diseased brain
por: Diaz-Aparicio, Irune, et al.
Publicado: (2016)

Matrix metalloproteinase activity stimulates N-cadherin shedding and the soluble N-cadherin ectodomain promotes classical microglial activation
por: Conant, Katherine, et al.
Publicado: (2017)

Neural grafting for Parkinson's disease: challenges and prospects
por: Stoker, Thomas B., et al.
Publicado: (2017)

Hydroxytyrosol Decreases LPS- and α-Synuclein-Induced Microglial Activation In Vitro
por: Gallardo-Fernández, Marta, et al.
Publicado: (2019)

A breakdown in microglial metabolic reprogramming causes internalization dysfunction of α-synuclein in a mouse model of Parkinson’s disease
por: Lu, Jia, et al.
Publicado: (2022)

Lentiviral Vectors Expressing Chimeric NEDD4 Ubiquitin Ligases: An Innovative Approach for Interfering with Alpha-Synuclein Accumulation
por: Vogiatzis, Stefania, et al.
Publicado: (2021)

Heterozygous carriers of galactocerebrosidase mutations that cause Krabbe disease have impaired microglial function and defective repair of myelin damage
por: Scott-Hewitt, Nicole J., et al.
Publicado: (2018)

Expression of mutant alpha-synuclein modulates microglial phenotype in vitro
por: Rojanathammanee, Lalida, et al.
Publicado: (2011)

The role of Galectin-3 in α-synuclein-induced microglial activation
por: Boza-Serrano, Antonio, et al.
Publicado: (2014)

Immunoregulation of microglial polarization: an unrecognized physiological function of α-synuclein
por: Li, Na, et al.
Publicado: (2020)

Regulation of α-synuclein homeostasis and inflammasome activation by microglial autophagy
por: Choi, Insup, et al.
Publicado: (2022)

Gene Therapy for the Treatment of Parkinson’s Disease: The Nature of the Biologics Expands the Future Indications
por: Fiandaca, Massimo S., et al.
Publicado: (2012)

Toll-Like Receptor 2 Signaling and Current Approaches for Therapeutic Modulation in Synucleinopathies
por: Caplan, Ian F., et al.
Publicado: (2018)

Alpha-Synuclein Aggregation in Parkinson's Disease
por: Srinivasan, E., et al.
Publicado: (2021)

Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition
por: Croisier, Emilie, et al.
Publicado: (2005)

α-Mangostin Inhibits α-Synuclein-Induced Microglial Neuroinflammation and Neurotoxicity
por: Hu, Zhaoyang, et al.
Publicado: (2016)

Molecular Signatures of Neuroinflammation Induced by αSynuclein Aggregates in Microglial Cells
por: Sarkar, Souvarish, et al.
Publicado: (2020)

Reply to Comment by Young et al.
por: Mathews, F., et al.
Publicado: (2009)

60404 HIV Tat Induced Neuroinflammation
por: Carey, Sean, et al.
Publicado: (2021)

Dopamine Agonist Therapy in Advanced Parkinson’s Disease
por: Reichmann, Heinz
Publicado: (2009)

Positron Emission Tomography in the Differential Diagnosis of Parkinsonism
por: Rinne, Juha O
Publicado: (2009)

The Epigenome as a therapeutic target for Parkinson's disease
por: Hegarty, Shane V., et al.
Publicado: (2016)

On the role of endogenous neurotoxins and neuroprotection in Parkinson's disease
por: Segura-Aguilar, Juan
Publicado: (2017)

There is more to NPH than lower body Parkinsonism
por: Oertel, Joachim M. K., et al.
Publicado: (2021)

Drug repurposing strategies of relevance for Parkinson’s disease
por: Fletcher, Edward J. R., et al.
Publicado: (2021)

Neuroinflammation in Parkinson’s Disease and its Treatment Opportunities
por: Çınar, Elif, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6dik8m91kgsi7bamuu6d382rhj